Spectrum Pharmaceuticals announced the commercial launch of Marqibo (vincristine sulfate liposome injection). Spectrum obtained marketing rights to Marqibo through the recent acquisition of Talon Therapeutics.
RELATED: Oncology Resource Center
Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine that is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following ≥2 anti-leukemia therapies.
The liposome encapsulation technology has been shown to provide prolonged circulation of vincristine in the blood.
Continue Reading
Marqibo can be accessed through Spectrum Therapy Access Resources (STAR) which is a reimbursement support, co-pay assistance, and patient assistance program designed to help patients and healthcare professionals gain appropriate access to drugs.
For more information call or visit Marqibo.com.
